Navigation Links
PTC Therapeutics To Present At The J.P. Morgan Healthcare Conference
Date:1/6/2014

SOUTH PLAINFIELD, N.J., Jan. 6, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 2014 J.P. Morgan Healthcare Conference on Monday, January 13 at 3:00 pm PT.

(Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com. The presentation will be archived for two weeks following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.

ABOUT PTC THERAPEUTICS, INC.

PTC is biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and which form the basis for collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website www.ptcbio.com.

FORWARD LOOKING STATEMENTS:

Any statements in this press release about future expectations, plans and prospects for PTC, the development of and potential market for our product candidates, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan" "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from those expressed or implied by these forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and conduct of clinical trials, availability of data from clinical trials, expectations for regulatory approvals, our scientific approach and general development progress, the availability or commercial potential of our product candidates and other factors discussed in the "Risk Factors" in the most recent Quarterly Report, which is on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views only as of the date of this release. We anticipate that subsequent events and developments will cause the our views to change. However, while PTC may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing PTC's views as of any date subsequent to the date of this press release.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... -- Perrigo Company plc (NYSE, TASE: PRGO) today announced it has ... for hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), 5 ... and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per ... in adults and children 6 years of age and older. ... approximately $16 million.   ...
(Date:2/17/2017)... , Feb. 17, 2017   FormFast , the ... a new partnership with Engage , one of ... States . FormFast will serve as the forms ... implementations with MEDITECH .  FormFast ... functionality to complement and enhance the electronic health record. ...
(Date:2/16/2017)... Pa. , Feb. 16, 2017 Absorption ... biologics, and medical devices, is pleased to announce that ... has been selected as a winner of the 2017 ... SmartCEO Magazine and recognizes driven executives for their ... work ethic. The awards ceremony and celebration is on ...
Breaking Medicine Technology:
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... is Dr. Carol Francis' goals for each and every seminar, session ... Carol Francis will demonstrate five different brainwave tools which help energize creativity, focus ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... and focusing on all facets of clinical trial planning and management. Pharmica discussed ... engagement, and more. In addition, attendees stopping by Pharmica’s booth were able to ...
(Date:2/17/2017)... ... 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial Hospital ... the Hospital Readmission Reduction Program (HRRP), the return of a patient to the hospital ... the nation. While many providers are struggling to leverage limited resources and technology, Onslow ...
(Date:2/17/2017)... ... February 17, 2017 , ... Dillon Ruxton Insurance, a Florida-based ... owners in the greater Fort Lauderdale metropolitan region, is embarking on a cooperative ... 30 years, LifeNet 4 Families has provided a broad range of food provision ...
Breaking Medicine News(10 mins):